Product Pipeline Compound Platform Indication Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA Partner Pidnarulex CX-5461 G-quadruplex (stabilizer) Breast Cancer (Completed) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA CA Dream team/CCTG Pidnarulex CX-5461 G-quadruplex (stabilizer) Ovarian Cancer/Breast/Other Cancer Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA/CA Pidnarulex CX-5461 G-quadruplex (stabilizer) Haematologic Malignancies (Completed) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA AU PMCC Pidnarulex CX-5461 G-quadruplex (stabilizer) Prostate Cancer Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA AU PCF/Pfizer/PMCC Pidnarulex CX-5461 G-quadruplex (stabilizer) Solid Tumors Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA NCI-NExT Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Cholangiocarcinoma (Completed) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA/KR/TW Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Basal cell carcinoma Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Medulloblastoma Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA PBTC/Stanford Univ. Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Community-Acquired Pneumonia Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA Taiwan/USA Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Neuroblastoma Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA PSU/BCC/Four Diamonds Foundation